The Latest Cardiac and Vascular News
The novel design of AtaCor’s EV-ICD Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies through an extravascular approach Initial cases demonstrated successful sensing and defibrillation of induced ventricular fibrillation with the Atala™ lead,…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. announced today that is has completed a $25M Series B financing. The financing syndicate, led by a corporate partner, includes existing investors Broadview Ventures and aMoon Fund as well as new investors Hatteras Venture Partners, Catalyst Health Ventures (CHV) and Longview Ventures, a Broadview affiliate. […]
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-based aMoon Ventures, the financing also includes participation from a corporate partner. The investment will support the continued development of AtaCor’s revolutionary extravascular substernal cardiac pacing […]
